A Jiffy Biomedical Primer for Generalist Investors
Covid has drawn unprecedented attention to the biomedical sector. As a corollary, many generalist investors are starting to take an interest in the sector.
https://viren-mahurkar.medium.com/a-jiffy-biomedical-primer-for-generalist-investors-a8ea7e724e7a
(please copy the above link and paste in your browser)
Biomedical M&A, BD&L and Investments; Board Roles
2 年https://www.nature.com/articles/d41586-022-00241-0
Biomedical M&A, BD&L and Investments; Board Roles
3 年https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived
Viren, a detailed (and heavy) primer on Gene Editing and continuation of cell therapy as two methods two solve (unsolved) health problems. I would commend the title as its a nice "jiffy" primer.
Biomedical M&A, BD&L and Investments; Board Roles
3 年https://endpts.com/top-gene-therapy-deals-ma-pacts-in-2020-highlight-another-big-year-in-one-of-the-hottest-fields-in-biopharma/
Biomedical M&A, BD&L and Investments; Board Roles
3 年Some analogous thoughts about digital health... https://medium.com/digitaldx/how-and-why-family-offices-should-consider-healthcare-venture-investments-27833be2c8a6